Forus Health

What Forus Health does

Forus Health Private Limited is a Bangalore-based medical device company founded in 2010 that builds AI-enabled retinal imaging platforms for ophthalmic diagnostics, with a primary focus on screening for diabetic retinopathy and other causes of preventable blindness. Its core product is a retinal imaging system that captures fundus images and, as of an October 2024 partnership with Google, integrates Google's AI model for automated diabetic retinopathy screening, enabling point-of-care diagnostics outside traditional specialist settings. The company serves B2B customers including hospitals, eye clinics, and diagnostic centers, particularly in India and other South Asian markets, with a stated ambition to expand globally following the November 2025 acquisition of a 21% stake by Inviga Healthcare Fund.

Forus Health makes money primarily through hardware sales of its retinal imaging devices to healthcare providers, with a layered AI software or platform-licensing component that introduces recurring revenue. Pricing is not publicly disclosed and is handled through enterprise procurement. The company is backed by tier-1 venture and healthcare investors including Accel, Chiratae Ventures, Asian Healthcare Fund, TPG NewQuest (now exited), and Inviga Healthcare Fund, and operates with a lean team of 51-100 employees. Its distribution relies on direct enterprise sales supplemented by strategic technology and investor partnerships intended to extend market reach.

The operating geographies are anchored in South Asia (India), and the company claims a broader global footprint. Leadership comprises co-founders Shyam Vasudeva Rao, Shyam Vasudev, and K. Chandrasekhar, supported by Chief Scientist Timothy Poston and CTO & Head of R&D Venkatakrishnan S, indicating a technology- and research-driven organization. The addressable market—AI-driven retinal screening devices—is projected to grow from $2.2 billion in 2025 to $7.1 billion in 2035 at a 12.6% CAGR, providing a favorable backdrop for the company's expansion strategy.

Name

Forus Health

Legal name

Forus Health Private Limited

Website

https://forushealth.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Forus Health is a Bangalore-based medical device company that builds AI-enabled retinal imaging platforms for diabetic retinopathy screening, selling hardware and AI-software solutions to hospitals, eye clinics, and diagnostic centers primarily in India with global expansion underway.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostic Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

akta.pro secondary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• Ophthalmic diagnostic devices
• Retinal imaging systems
• Diabetic retinopathy screening
• AI eye screening
• Preventive eye care

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of AI-powered retinal imaging devices and screening equipment to healthcare providers, hospitals, and eye clinics
2. AI Software/Platform Licensing: AI-powered diagnostic software integrated into retinal imaging devices, potentially offered as platform or licensing model

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Forus Health develops and sells AI-powered retinal imaging devices used by healthcare providers to screen patients for diabetic retinopathy and other ocular conditions. The platform combines proprietary retinal imaging hardware with AI-driven diagnostic software, including an integration of Google's AI model for diabetic retinopathy screening. The devices enable point-of-care screening in hospitals, eye clinics, and diagnostic centers, particularly in underserved areas.

Product overview

Forus Health offers a unified retinal imaging platform with integrated AI-powered screening capabilities. The core platform combines hardware (retinal imaging devices) with software analytics to enable automated diabetic retinopathy screening. In October 2024, the platform was enhanced through a partnership with Google to integrate Google's AI model for diabetic retinopathy detection. The company operates in the ophthalmic diagnostics sector, serving healthcare providers with accessible solutions for preventable blindness screening.

Differentiator

Problem solved

Functional benefit

Products and services

• Forus Health Retinal Imaging Platform Ophthalmic diagnostics platform combining proprietary retinal imaging hardware (specialized retinal cameras capturing fundus images) with AI-driven diagnostic software for automated detection of diabetic retinopathy and other ocular conditions. Targeted at hospitals, eye clinics, and diagnostic centers for point-of-care screening.

Quantifiable outcome

• Global AI-driven retinal screening device market growing from $2.2B (2025) to $7.1B (2035) at 12.6% CAGR

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature2 records

Partnerships

One partnership is on record.

• GooglecoreTechnology or Integration · 1 October 2024Forus Health partnered with Google in October 2024 to integrate Google's AI model for diabetic retinopathy screening into Forus's retinal imaging platform. This partnership enhances Forus's AI capabilities for automated screening of diabetic retinopathy, a leading cause of preventable blindness.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Digital Diagnostics (IDx): Pioneer in autonomous AI for diabetic retinopathy diagnosis (IDx-DR), offering a direct competitive benchmark in AI-based point-of-care DR screening.
• Remidio Innovative Solutions: India-based ophthalmic device company producing AI-enabled retinal imaging systems (e.g., NM-Slitlamp, 3nethra-like devices), competing with Forus in both Indian and emerging markets.
• Eyenuk: US-based developer of EyeArt, an FDA-cleared autonomous AI system for diabetic retinopathy screening, directly comparable to Forus Health's Google-AI-powered DR screening platform.
• Airdoc: AI-driven retinal image analysis company offering mass screening solutions for systemic and ocular diseases, directly overlapping with Forus's AI retinal screening use case.

Broad incumbents

• ZEISS Medical Technology: Global leader in ophthalmic devices including fundus cameras and OCT systems; competes with Forus in retinal imaging hardware while also integrating AI into its platform.
• Heidelberg Engineering: Established manufacturer of diagnostic imaging devices (Spectralis OCT, fundus imaging) used by retina specialists, representing the incumbent standard Forus is positioning against.
• Topcon Healthcare: Major ophthalmic imaging and healthcare solutions company with AI-enabled fundus and OCT products, including the Harmony/RDOSS DR screening platform — directly relevant to Forus's market.
• Optos (Nikon Healthcare): Provider of ultra-widefield retinal imaging devices used in DR screening and retina specialty clinics, representing a key incumbent in the same end-market as Forus Health.

Emerging players

• 12 Sigma Technologies: AI medical imaging company whose products include AI-based DR detection, positioning it as an emerging competitor in autonomous retinal screening alongside Forus.
• Phelcom Technologies: Brazil-based developer of portable, AI-powered retinal imaging devices (e.g., Eyer) targeting DR screening in underserved settings — directly comparable to Forus's portable, point-of-care screening model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/forus_health
• Facebookfacebook.com/forushealth
• LinkedInlinkedin.com/company/forus-health-pvt.-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Forus Health